A recent study showed that RON is increasingly expressed during progression of pancreatic cancer (68) and that RON shows sustained expression in pancreatic cancer stem cells [69] suggesting its potential value as a therapeutic target for this disease. Here, MST1R is linked to pancreatic neoplasm.